Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.

Abstract

Cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4) is an important costimultory receptor expressed on activated T cells. CTLA-4 blockade using a monoclonal antibody (mAb) in conjunction with tumor vaccines has improved tumor responses in animal models and enhanced numerous models of T cell-associated autoimmune diseases. Two patients with stage IV metastatic melanoma vaccinated with the gp 100 melanocyte/melanoma differentiation antigen either before or during anti-CTLA-4 mAb therapy developed uveitis. This is the first report of autoimmune disease involving the eye in patients treated with anti-CTLA-4 mAb. This suggests that CTLA-4 is an important regulatory molecule for maintenance of tolerance to melanosomal antigens and prevention of uveitis.

• Authors: Michael R Robinson, Chi-Chao Chan, James C Yang, Benjamin I Rubin, Gerald J Gracia, H Nida Sen, Karl G Csaky, Steven A Rosenberg
• Journal: Journal of immunotherapy (Hagerstown, Md. : 1997) (J Immunother) 2004 Nov-Dec Vol. 27 Issue 6 Pg. 478-9 ISSN: 1524-9557 [Print] United States
• PMID: 15534492 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antigens, CD
• Antigens, Differentiation
• CTLA-4 Antigen
• CTLA4 protein, human
• Membrane Glycoproteins
• Neoplasm Proteins
• PMEL protein, human
• gp100 Melanoma Antigen

Topics

• Antibodies, Monoclonal (immunology, therapeutic use)
• Antigens, CD
• Antigens, Differentiation (immunology)
• Autoimmune Diseases (immunology)
• CTLA-4 Antigen
• Female
• Humans
• Male
• Melanoma (complications, drug therapy, immunology)
• Membrane Glycoproteins (immunology)
• Middle Aged
• Neoplasm Proteins (immunology)
• Neoplasm Staging
• T-Lymphocytes, Cytotoxic (immunology)
• Uvea (pathology)
• Uveitis (immunology)
• gp100 Melanoma Antigen